logo.jpg
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
September 18, 2024 05:00 ET | ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
logo.jpg
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
May 30, 2024 08:00 ET | ImCheck Therapeutics SAS
ImCheck to Present Promising ICT01 Datafrom the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination...
logo.jpg
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
November 03, 2023 14:00 ET | ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
logo.jpg
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
October 30, 2023 06:41 ET | ImCheck Therapeutics SAS
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting          Marseille, France, October 30, 2023 – ImCheck...
logo.jpg
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
March 23, 2023 03:00 ET | ImCheck Therapeutics SAS
ImCheck Appoints Thomas Civik as Independent Chairman of the Board         Marseille, France, March 23, 2023 – ImCheck Therapeutics announced today the appointment of Thomas Civik as independent...
logo.jpg
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
March 14, 2023 17:30 ET | ImCheck Therapeutics SAS
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR          Marseille, France, March 14, 2023 – ImCheck Therapeutics...
logo.jpg
Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
September 10, 2022 09:15 ET | ImCheck Therapeutics SAS
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more checkpoint-inhibitor regimen, across a range of ICT01 doses in...
logo.jpg
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
April 08, 2022 13:00 ET | ImCheck Therapeutics SAS
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Datafrom the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022         Continued positive safety data across a range of ICT01 doses...
logo.jpg
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
February 03, 2022 05:03 ET | ImCheck Therapeutics SAS
ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01          EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...
logo.jpg
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022 06:00 ET | ImCheck Therapeutics SAS
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference         Marseille, France, January 6, 2022 – ImCheck Therapeutics announced today that its Chief Executive Officer, Pierre...